CD276 antibody

Catalog No. ABIN2664487

The Rat Monoclonal anti-CD276 antibody has been validated for FACS. It is suitable to detect CD276 in samples from Human and Mouse.

Quick Overview for CD276 antibody (ABIN2664487)

Target: CD276

Reactivity: Human, Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD276 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: MIH35

Product Details anti-CD276 Antibody

Cross-Reactivity: Human

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD276

Target: CD276

Alternative Name: CD276

Background: B7-H3 is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins. B7-H3 is mostly expressed on professional APCs including B cells, macrophages, and dendritic cells at low level. It is detected on various human and murine tumor cells, nasal and airway epithelial cells. Its expression on dendritic cells appears to be up-regulated by LPS. Initial studies have shown that B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. Mouse B7-H3 protein inhibited T cell activation and effector cytokine production. Thus, the immunological function of B7-H3 remains unclear. B7-H3 is involved in the suppression of Th1-mediated immune responses and plays an important role in the development of pathogenic Th2 cells in a murine asthma model. Monoclonal antibody against B7-H3 enhances T cell proliferation in vitro and leads to exacerbated EAE in vivo. It was reported recently that the Triggering Receptor Expressed on Myeloid cells (TREM)-like Transcript 2 (TLT-2, TREML2) is a receptor for B7-H3 in mice. It remains controversial. Further studies are needed to identify the receptor of B7-H3.

Pathways: Cancer Immune Checkpoints